|
[1] MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases:A review of the literature[J]. Int J Mol Sci, 2019, 20 (2) :e395.
|
|
[2]LVAREZ-MERCADO AI, NAVARRO-OLIVEROS M, ROBLES-SNCHEZ C, et al. Microbial population changes and their relationship with human health and disease[J]. Microorganisms, 2019, 7 (3) :e68.
|
|
[3] KHO ZY, LAL SK. The human gut microbiome-a potential controller of wellness and disease[J]. Front Microbiol, 2018, 9:1835.
|
|
[4] CHOU HH, CHIEN WH, WU LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112 (7) :2175-2180.
|
|
[5] KANG Y, CAI Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J]. J Hosp Infect, 2017, 96 (4) :342-348.
|
|
[6] REN YD, YE ZS, YANG LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBe Ag) clearance in patients with positive HBe Ag after long-term antiviral therapy[J]. Hepatology, 2017, 65 (5) :1765-1768.
|
|
[7] INOUE T, NAKAYAMA J, MORIYA K, et al. Gut dysbiosis associated with hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67 (6) :869-877.
|
|
[8] LI F, SUN G, WANG Z, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci, 2018, 61 (7) :770-778.
|
|
[9] BRANDL K, SCHNABL B. Intestinal microbiota and nonalcoholic steatohepatitis[J]. Curr Opin Gastroenterol, 2017, 33 (3) :128-133.
|
|
[10] BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.
|
|
[11] SAFARI Z, GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD) [J]. Cell Mol Life Sci, 2019, 76 (8) :1541-1558.
|
|
[12] MA J, ZHOU Q, LI H. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanisms and therapy[J]. Nutrients, 2017, 9 (10) :e1124.
|
|
[13] BOMHOF MR, PARNELL JA, RAMAY HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic:A pilot clinical trial[J]. Eur J Nutr, 2018, 58 (4) :1735-1745.
|
|
[14] KHALESI S, JOHNSON DW, CAMPBELL K, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes:A systematic review and meta-analysis[J]. Eur J Nutr, 2018, 57 (6) :2037-2053.
|
|
[15] MENG X, LI S, LI Y, et al. Gut microbiota's relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics[J]. Nutrients, 2018, 10 (10) :e1457.
|
|
[16] CASSARD AM, CIOCAN D. Microbiota, a key player in alcoholic liver disease[J]. Clin Mol Hepatol, 2018, 24 (2) :100-107.
|
|
[17] STRKEL P, LECLERCQ S, de TIMARY P, et al. Intestinal dysbiosis and permeability:The yin and yang in alcohol dependence and alcoholic liver disease[J]. Clin Sci (Lond) , 2018, 132 (2) :199-212.
|
|
[18] LLOPIS M, CASSARD AM, WRZOSEK L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016, 65 (5) :830-839.
|
|
[19] KONTUREK PC, HARSCH IA, KONTUREK K, et al. Gut-liver axis:How do gut bacteria influence the liver?[J]. Med Sci (Basel) , 2018, 6 (3) :e79.
|
|
[20] LI F, DUAN K, WANG C, et al. Probiotics and alcoholic liver disease:Treatment and potential mechanisms[J]. Gastroenterol Res Pract, 2016, 2016:5491465.
|
|
[21] PHILIPS CA, PHADKE N, GANESAN K, et al. Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis[J]. BMJ Case Rep, 2017. pii:bcr-2017-222310.
|
|
[22] ZHANG X, WANG H, YIN P, et al. Flaxseed oil ameliorates alcoholic liver disease via anti-inflammation and modulating gut microbiota in mice[J]. Lipids Health Dis, 2017, 16 (1) :44.
|
|
[23] MATTNER J. Impact of microbes on the pathogenesis of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) [J]. Int J Mol Sci, 2016, 17 (11) :e1864.
|
|
[24] TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67 (3) :534-541.
|
|
[25] WEI X, ZHAO JT, JIA XD, et al. Abnormal gut microbiota metabolism specific for liver cirrhosis[J]. Front Microbiol, 2018, 9:3051.
|
|
[26] GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis:Rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46 (11-12) :1029-1036.
|
|
[27] KIMER N, PEDERSEN JS, BUSK TM, et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis:A randomized, double-blind, placebo-controlled trial[J]. Hepatology, 2017, 65 (2) :592-603.
|
|
[28] KIMER N, PEDERSEN JS, TAVENIER J, et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis:A randomized trial[J]. J Gastroenterol Hepatol, 2018, 33 (1) :307-314.
|
|
[29] CAO Q, YU CB, YANG SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy:A meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17 (1) :9-16.
|
|
[30] ALTAMIRANO-BARRERA A, URIBE M, CHVEZ-TAPIA NC, et al. The role of the gut microbiota in the pathology and prevention of liver disease[J]. J Nutr Biochem, 2018, 60:1-8.
|
|
[31] BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J]. Hepatology, 2017, 66 (6) :1727-1738.
|
|
[32] PONZIANI FR, BHOORI S, CASTELLI C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 69 (1) :107-120.
|
|
[33] MA C, HAN M, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360 (6391) . pii:eaan5931.
|
|
[34] HOU J, LU Y, ZHANG DK. Association between intestinal dysbacteriosis and liver diseases[J]. J Clin Hepatol, 2018, 34 (5) :1128-1132. (in Chinese) 侯静, 路越, 张德凯.肠道菌群失调与肝脏疾病的关系[J].临床肝胆病杂志, 2018, 34 (5) :1128-1132.
|
|
[35] HUANG R, NI JJ, GAO Y. The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.
|
|
[36] LI J, SUNG CY, LEE N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A, 2016, 113 (9) :e1306-e1315.
|
DownLoad: